Hollow Brook Wealth Management LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Hollow Brook Wealth Management LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 28.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,326 shares of the biopharmaceutical company’s stock after purchasing an additional 13,041 shares during the period. Hollow Brook Wealth Management LLC’s holdings in Pfizer were worth $1,679,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the third quarter valued at approximately $30,000. Mizuho Securities Co. Ltd. purchased a new position in shares of Pfizer during the third quarter valued at approximately $34,000. VisionPoint Advisory Group LLC increased its stake in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC increased its stake in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Finally, Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Stock Down 0.1 %

Shares of PFE stock traded down $0.03 during mid-day trading on Tuesday, hitting $25.61. The company’s stock had a trading volume of 37,889,007 shares, compared to its average volume of 41,962,758. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The business has a 50-day moving average price of $26.88 and a 200 day moving average price of $28.26. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a market cap of $145.02 billion, a price-to-earnings ratio of 71.14, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 earnings per share. Research analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.56%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.